A Phase IIb multicentre, randomised, double-blind, two-arm trial comparing the efficacy and safety of 25 mg psilocybin plus psychological support versus 5 mg psilocybin plus psychological support in adults with severe generalized anxiety disorder (GAD) (PSiGAD2)
Latest Information Update: 03 Oct 2024
At a glance
- Drugs Psilocybin (Primary)
- Indications Generalised anxiety disorder
- Focus Registrational; Therapeutic Use
- Acronyms PSiGAD2
- Sponsors Incannex Healthcare
Most Recent Events
- 03 Aug 2022 New trial record